Pulse Biosciences reported FY 2025 revenue of USD 350 thousand and Q4 2025 revenue of USD 264 thousand, up 3.07x versus Q3 2025. Q4 2025 GAAP net loss was USD 17.4 million and non-GAAP net loss was USD 12.2 million; FY 2025 GAAP net loss was USD 72.8 million and non-GAAP net loss was USD 50.8 million. Q4 2025 GAAP costs and expenses were USD 18.5 million, while FY 2025 GAAP costs and expenses were USD 77.3 million (+37.32% YoY), driven primarily by expenses related to an expanding organization to support nsPFA device clinical trials and commercialization. Cash and cash equivalents were USD 80.7 million at Dec. 31, 2025. On business updates, Pulse Biosciences highlighted late-breaking feasibility data for its nPulse Cardiac Catheter System showing 100% procedural success (freedom from atrial fibrillation) at six months and 96% at one year in evaluable patients. The company said it received FDA approval in Q4 2025 to commence a pivotal IDE study for paroxysmal atrial fibrillation, with the first patient expected to be enrolled in the next few months and the last patient expected in Q4 2026. Pulse Biosciences also said it continued enrollment in its surgical AF ablation IDE pivotal study, NANOCLAMP AF, and is expanding and accelerating IDE site activation to support enrollment completion in 2026. In soft tissue ablation, the company reported USD 264 thousand of revenue from a “highly controlled commercial launch,” continued enrollment in the PRECISE-BTN benign thyroid nodule study with plans to complete 50 patients in the next few months and expand to 100 patients over the ensuing two quarters, and initiated a research collaboration with The University of Texas MD Anderson Cancer Center to evaluate nsPFA in benign and malignant thyroid tumors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191605BIZWIRE_USPR_____20260219_BW281220) on February 19, 2026, and is solely responsible for the information contained therein.
Comments